Ceylan Emel, Bulut Sertan, Yilmaz Mustafa, Örün Hüseyin, Karadağ Fisun, Ömürlü İmran Kurt, Kirdar Sevin, Karul Aslıhan
Department of Pulmonary Medicine, Adnan Menderes University Medical School, Aydın, Turkey.
Department of Pulmonary Medicine, Atatürk Chest Diseases and Chest Surgery Education and Research Hospital, Ankara, Turkey.
Iran J Allergy Asthma Immunol. 2019 Feb;18(1):27-37.
The effects of comorbidities on systemic inflammation markers in stable asthmatics and the consequences of such effects have not been well evaluated. We aimed to evaluate the effect of comorbidities on clinical manifestations and systemic inflammation in asthmatic patients under control. The study group consisted of asthmatic patients who applied to our pulmonology outpatient clinic and volunteered to participate. 120 clinically stable asthma patients (71 females and 49 males) and 35 healthy controls (19 females and 16 males) with similar age, gender, and body mass index distributions were admitted to the study. The levels of osteopontin, interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 13 (IL-13), eosinophilic cationic protein, adiponectin, and high-sensitivity C-reactive protein of the individuals were evaluated using commercial ELISA kits by taking venous blood samples. Of 120 asthmatic subjects, 47 (39, 2%) had comorbidities and allergic rhinitis (15%) coexisted most frequently. Other comorbidities associated with asthma were gastroesophageal reflux, sinusitis, hypertension, diabetes, gastritis, and peptic ulcus respectively. There was no physician-diagnosed comorbidity in the control group. The levels of IL-6 and IL-8 were found higher in asthma group with comorbidities when compared to those with no comorbidities (p were 0.032 and 0.046, respectively). Comorbidities interfere with the diagnosis and treatment of asthma, besides affecting the disease control. Our findings suggest the possibility of the impact of comorbidities on systemic inflammation markers, especially IL-6 and IL-8. To evaluate the impact of comorbidities on asthma control and systemic markers, further studies are needed.
合并症对稳定期哮喘患者全身炎症标志物的影响及其后果尚未得到充分评估。我们旨在评估合并症对病情得到控制的哮喘患者临床表现和全身炎症的影响。研究组由前来我院肺科门诊就诊并自愿参与的哮喘患者组成。120例临床稳定的哮喘患者（71例女性和49例男性）和35例年龄、性别和体重指数分布相似的健康对照者（19例女性和16例男性）纳入研究。通过采集静脉血样本，使用商用酶联免疫吸附测定试剂盒评估个体的骨桥蛋白、白细胞介素6（IL-6）、白细胞介素8（IL-8）、白细胞介素13（IL-13）、嗜酸性阳离子蛋白、脂联素和高敏C反应蛋白水平。在120例哮喘患者中，47例（39.2%）有合并症，其中变应性鼻炎（15%）最为常见。与哮喘相关的其他合并症分别为胃食管反流、鼻窦炎、高血压、糖尿病、胃炎和消化性溃疡。对照组无医生诊断的合并症。与无合并症的哮喘组相比，有合并症的哮喘组IL-6和IL-8水平更高（p值分别为0.032和0.046）。合并症除影响哮喘控制外，还会干扰哮喘的诊断和治疗。我们的研究结果提示合并症可能影响全身炎症标志物，尤其是IL-6和IL-8。为评估合并症对哮喘控制和全身标志物的影响，还需要进一步研究。
